-
Something wrong with this record ?
Enantioseparation and impurity determination of ambrisentan using cyclodextrin-modified micellar electrokinetic chromatography: Visualizing the design space within quality by design framework
S. Orlandini, B. Pasquini, C. Caprini, M. Del Bubba, M. Douša, S. Pinzauti, S. Furlanetto,
Language English Country Netherlands
Document type Journal Article
- MeSH
- Borates chemistry MeSH
- Chromatography, Micellar Electrokinetic Capillary * methods MeSH
- Cyclodextrins MeSH
- Sodium Dodecyl Sulfate MeSH
- Phenylpropionates analysis chemistry MeSH
- Calibration MeSH
- Hydrogen-Ion Concentration MeSH
- Drug Contamination MeSH
- Buffers MeSH
- Pyridazines analysis chemistry MeSH
- Reproducibility of Results MeSH
- Quality Control MeSH
- Stereoisomerism MeSH
- Tablets analysis MeSH
- Publication type
- Journal Article MeSH
A capillary electrophoresis method for the simultaneous determination of the enantiomeric purity and of impurities of the chiral drug ambrisentan has been developed following the Quality by Design principles. The selected separation system consisted of a micellar pseudostationary phase made by sodium dodecyl sulphate with the addition of γ-cyclodextrin. The effects of critical process parameters (capillary length, temperature, voltage, borate concentration, pH, sodium dodecyl sulphate concentration, γ-cyclodextrin concentration) on enantioresolution of ambrisentan and analysis time were extensively investigated by multivariate strategies involving a screening phase and Response Surface Methodology. The Design Space was defined with a desired probability level π≥90%, and the working conditions, with the limits of the Design Space, corresponded to the following: capillary length, 64.5cm; temperature, 22°C; voltage, 30kV (26-30kV); background electrolyte, 100mM borate buffer pH 9.20 (8.80-9.60), 100mM sodium dodecyl sulphate, 50mM (43-50mM) γ-cyclodextrin. A Plackett-Burman design was applied for robustness testing, and a method control strategy was established. The method was fully validated according to the International Conference on Harmonisation guidelines and was applied to ambrisentan coated tablets.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000243
- 003
- CZ-PrNML
- 005
- 20170103132946.0
- 007
- ta
- 008
- 170103s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.chroma.2016.06.082 $2 doi
- 024 7_
- $a 10.1016/j.chroma.2016.06.082 $2 doi
- 035 __
- $a (PubMed)27425759
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Orlandini, S $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.
- 245 10
- $a Enantioseparation and impurity determination of ambrisentan using cyclodextrin-modified micellar electrokinetic chromatography: Visualizing the design space within quality by design framework / $c S. Orlandini, B. Pasquini, C. Caprini, M. Del Bubba, M. Douša, S. Pinzauti, S. Furlanetto,
- 520 9_
- $a A capillary electrophoresis method for the simultaneous determination of the enantiomeric purity and of impurities of the chiral drug ambrisentan has been developed following the Quality by Design principles. The selected separation system consisted of a micellar pseudostationary phase made by sodium dodecyl sulphate with the addition of γ-cyclodextrin. The effects of critical process parameters (capillary length, temperature, voltage, borate concentration, pH, sodium dodecyl sulphate concentration, γ-cyclodextrin concentration) on enantioresolution of ambrisentan and analysis time were extensively investigated by multivariate strategies involving a screening phase and Response Surface Methodology. The Design Space was defined with a desired probability level π≥90%, and the working conditions, with the limits of the Design Space, corresponded to the following: capillary length, 64.5cm; temperature, 22°C; voltage, 30kV (26-30kV); background electrolyte, 100mM borate buffer pH 9.20 (8.80-9.60), 100mM sodium dodecyl sulphate, 50mM (43-50mM) γ-cyclodextrin. A Plackett-Burman design was applied for robustness testing, and a method control strategy was established. The method was fully validated according to the International Conference on Harmonisation guidelines and was applied to ambrisentan coated tablets.
- 650 _2
- $a boritany $x chemie $7 D001881
- 650 _2
- $a pufry $7 D002021
- 650 _2
- $a kalibrace $7 D002138
- 650 12
- $a chromatografie micelární elektrokinetická kapilární $x metody $7 D020374
- 650 _2
- $a cyklodextriny $7 D003505
- 650 _2
- $a kontaminace léku $7 D004340
- 650 _2
- $a koncentrace vodíkových iontů $7 D006863
- 650 _2
- $a fenylpropionáty $x analýza $x chemie $7 D010666
- 650 _2
- $a pyridaziny $x analýza $x chemie $7 D011724
- 650 _2
- $a řízení kvality $7 D011786
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a dodecylsíran sodný $7 D012967
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a tablety $x analýza $7 D013607
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pasquini, B $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.
- 700 1_
- $a Caprini, C $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.
- 700 1_
- $a Del Bubba, M $u Department of Chemistry "U. Schiff", University of Florence, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Florence, Italy.
- 700 1_
- $a Douša, M $u Zentiva, k.s. Praha, a Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
- 700 1_
- $a Pinzauti, S $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.
- 700 1_
- $a Furlanetto, S $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy. Electronic address: sandra.furlanetto@unifi.it.
- 773 0_
- $w MED00004962 $t Journal of chromatography. A $x 1873-3778 $g Roč. 1467, č. - (2016), s. 363-371
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27425759 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170103133033 $b ABA008
- 999 __
- $a ok $b bmc $g 1179383 $s 960810
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 1467 $c - $d 363-371 $e 20160701 $i 1873-3778 $m Journal of chromatography. A, Including electrophoresis and other separation methods $n J Chromatogr A $x MED00004962
- LZP __
- $a Pubmed-20170103